Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa: Abecma in Relapsed and Refractory Multiple Myeloma
NCT03361748Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2017
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 8
01
Overview
A Phase 2 trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Celgene Corporation. Started Dec 2017; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03361748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361748.